Molecular events linking cholesterol to alzheimer’s disease and inclusion body myositis in a rabbit model

American Journal of Neurodegenerative Diseases

Volumn 5, Issue 1, 2016, Pages 74-84

  Liu, Qing Yan ^a,b   Koukiekolo, Roger ^a   Zhang, Dong Ling ^a   Smith, Brandon ^a   Ly, Dao ^a   Lei, Joy X ^a   Ghribi, Othman ^c  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Alzheimer s disease; Gene expression; Hemoglobin; Mitochondrial oxidative phosphorylation; Nucleotide microarray; Rabbit AD model; SIBM

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; HEMOGLOBIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DIETARY INTAKE; DNA MICROARRAY; GENE EXPRESSION; MALE; MICROARRAY ANALYSIS; MITOCHONDRIAL RESPIRATION; MOLECULAR BIOLOGY; MUSCLE WEAKNESS; MYOSITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR;

EID: 84980052290     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Taylor JP, Hardy J and Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002; 296: 1991-1995.
2. St George-Hyslop PH. Molecular genetics of Alzheimer disease. Semin Neurol 1999; 19: 371-383.
3. Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer’s disease. Trends Mol Med 2010; 16: 287-294.
4. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, Heun R, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van BC, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O’Donovan M, Owen MJ and Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 2009; 41: 1088-1093.
5. Bjorkhem I and Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004; 24: 806-815.
6. Huang Y. Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. Curr Opin Drug Discov Devel 2006; 9: 627-641.
7. Miller LJ and Chacko R. The role of cholesterol and statins in Alzheimer’s disease. Ann Pharmacother 2004; 38: 91-98.
8. Puglielli L, Tanzi RE and Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci 2003; 6: 345-351.
9. Wolozin B. A fluid connection: cholesterol and Abeta. Proc Natl Acad Sci U S A 2001; 98: 5371-5373.
10. Wolozin B. Cholesterol and the biology of Alzheimer’s disease. Neuron 2004; 41: 7-10.
11. Askanas V, Engel WK and Nogalska A. Sporadic inclusion-body myositis: A degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochim Biophys Acta 2015; 1852: 633-643.
12. Askanas V and Engel WK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding and proteasome inhibition. Neurology 2006; 66: S39-S48.
13. Askanas V and Engel WK. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains. Acta Neuropathol 2008; 116: 583-595.
14. Liu QY, Sooknanan RR, Malek LT, Ribecco-Lutkiewicz M, Lei JX, Shen H, Lach B, Walker PR, Martin J and Sikorska M. Novel subtractive transcription-based amplification of mRNA (STAR) method and its application in search of rare and differentially expressed genes in AD brains. BMC Genomics 2006; 7: 286.
15. Murphy MP and Golde TE. Inclusion-body myositis and Alzheimer disease: two sides of the same coin, or different currencies altogether? Neurology 2006; 66: S65-S68.
16. Reddy PH and McWeeney S. Mapping cellular transcriptosomes in autopsied Alzheimer’s disease subjects and relevant animal models. Neurobiol Aging 2006; 27: 1060-1077.
17. Upadhya SC and Hegde AN. Role of the ubiquitin proteasome system in Alzheimer’s disease. BMC Biochem 2007; 8 Suppl 1: S12.
18. Levacic D, Peddareddygari LR, Nochlin D, Sharer LR and Grewal RP. Inclusion-body myositis associated with Alzheimer’s disease. Case Rep Med 2013; 2013: 536231
19. Roos PM, Vesterberg O and Nordberg M. Inclusion body myositis in Alzheimer’s disease. Acta Neurol Scand 2011; 124: 215-217.
20. Ghribi O, Golovko MY, Larsen B, Schrag M and Murphy EJ. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem 2006; 99: 438-449.
21. Ghribi O, Larsen B, Schrag M and Herman MM. High cholesterol content in neurons increases BACE, beta-amyloid and phosphorylated tau levels in rabbit hippocampus. Exp Neurol 2006; 200: 460-467.
22. Ghribi O. Potential mechanisms linking cholesterol to Alzheimer’s disease-like pathology in rabbit brain, hippocampal organotypic slices and skeletal muscle. J Alzheimers Dis 2008; 15: 673-684.
23. Schreurs BG. Cholesterol and Copper Affect Learning and Memory in the Rabbit. Int J Alzheimers Dis 2013; 518780.
24. Sparks DL. The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimer’s disease: the old, the new and the pilot. J Alzheimers Dis 2008; 15: 641-656.
25. Woodruff-Pak DS, Agelan A and Del VL. A rabbit model of Alzheimer’s disease: valid at neuropathological, cognitive and therapeutic levels. J Alzheimers Dis 2007; 11: 371-383.
26. Chen X, Ghribi O and Geiger JD. Rabbits fed cholesterol-enriched diets exhibit pathological features of inclusion body myositis. Am J Physiol Regul Integr Comp Physiol 2008; 294: R829-R835.
27. Liu QY, Bingham EJ, Twine SM, Geiger JD and Ghribi O. Metabolomic Identification in Cerebrospinal Fluid of the Effects of High Dietary Cholesterol in a Rabbit Model of Alzheimer’s Disease. Metabolomics 2012; 2: 109.
28. Liu QY, Chang MN, Lei JX, Koukiekolo R, Smith B, Zhang D and Ghribi O. Identification of microRNAs involved in Alzheimer’s progression using a rabbit model of the disease. Am J Neurodegener Dis 2014; 3: 33-44.
29. Huang TC, Lu KT, Wo YYP, Wu YJ and Yang YL. Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One 2011; 6: e29102.
30. Loring JF, Wen X, Lee JM, Seilhamer J and Somogyi R. A gene expression profile of Alzheimer’s disease. DNA Cell Biol 2001; 20: 683-695.
31. Ricciarelli R, D’Abramo C, Zingg JM, Giliberto L, Markesbery W, Azzi A, Marinari UM, Pronzato MA and Tabaton M. CD36 overexpression in human brain correlates with beta-amyloid deposition but not with Alzheimer’s disease. Free Radic Biol Med 2004; 36: 1018-1024.
32. Mangialasche F, Baglioni M, Cecchetti R, Kivipelto M, Ruggiero C, Piobbico D, Kussmaul L, Monastero R, Brancorsini S and Mecocci P. Lymphocytic mitochondrial aconitase activity is reduced in Alzheimer’s disease and mild cognitive impairment. J Alzheimers Dis 2015; 44: 649-660.
33. Walker PR, Smith B, Liu QY, Famili AF, Valdes JJ, Liu Z and Lach B. Data mining of gene expression changes in Alzheimer brain. Artif Intell Med 2004; 31: 137-154.
34. Wu CW, Liao PC, Yu L, Wang ST, Chen ST, Wu CM and Kuo YM. Hemoglobin promotes Abeta oligomer formation and localizes in neurons and amyloid deposits. Neurobiol Dis 2004; 17: 367-377.
35. Chuang JY, Lee CW, Shih YH, Yang T, Yu L and Kuo YM. Interactions between amyloid-beta and hemoglobin: implications for amyloid plaque formation in Alzheimer’s disease. PLoS One 2012; 7: e33120.
36. Tezel G, Yang X, Luo C, Cai J, Kain AD, Powell DW, Kuehn MH and Pierce WM. Hemoglobin expression and regulation in glaucoma: insights into retinal ganglion cell oxygenation. Invest Ophthalmol Vis Sci 2010; 51: 907-919.
37. Wang GL and Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993; 90: 4304-4308.
38. Zhou D, Wang J, Zapala MA, Xue J, Schork NJ and Haddad GG. Gene expression in mouse brain following chronic hypoxia: role of sarcospan in glial cell death. Physiol Genomics 2008; 32: 370-379.
39. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci 2004; 5: 347-360.
40. Stone J. What initiates the formation of senile plaques? The origin of Alzheimer-like dementias in capillary haemorrhages. Med Hypotheses 2008; 71: 347-359.
41. Buchwald H, O’Dea TJ, Menchaca HJ, Michalek VN and Rohde TD. Effect of plasma cholesterol on red blood cell oxygen transport. Clin Exp Pharmacol Physiol 2000; 27: 951-955.
42. Sparks LM, Xie H, Koza RA, Mynatt R, Hulver MW, Bray GA and Smith SR. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes 2005; 54: 1926-1933.
43. Kong W, Mou X, Liu Q, Chen Z, Vanderburg CR, Rogers JT and Huang X. Independent component analysis of Alzheimer’s DNA microarray gene expression data. Mol Neurodegener 2009; 4: 5.
44. Windisch M, Hutter-Paier B, Schreiner E and Wronski R. Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders? J Mol Neurosci 2004; 24: 155-165.
45. Ginsberg SD, Hemby SE, Lee VM, Eberwine JH and Trojanowski JQ. Expression profile of transcripts in Alzheimer’s disease tangle-bearing CA1 neurons. Ann Neurol 2000; 48: 77-87.
46. Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D and Masliah E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer’s disease. Brain Res 2001; 914: 48-56.
47. Ltic S, Perovic M, Mladenovic A, Raicevic N, Ruzdijic S, Rakic L and Kanazir S. Alphasynuclein is expressed in different tissues during human fetal development. J Mol Neurosci 2004; 22: 199-204.
48. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P and Chilcote TJ. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 2008; 5: 55-59.
49. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, Ney PA, Ng J, McGoldrick M, Mollenhauer B, Bresnick EH and Schlossmacher MG. GATA transcription factors directly regulate the Parkinson’s diseaselinked gene alpha-synuclein. Proc Natl Acad Sci U S A 2008; 105: 10907-10912.
50. Askanas V, Engel WK, Alvarez RB, McFerrin J and Broccolini A. Novel immunolocalization of alpha-synuclein in human muscle of inclusionbody myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol 2000; 59: 592-598.